Georgia's Online Cancer Information Center


back

Multiple Myeloma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Multiple Myeloma
Cancer Type = Multiple Myeloma
NCI ID Cancer Type Trial Name
There are currently 45 active Multiple Myeloma clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT05675449
Protocol IDs
C1071020
NCI-2023-01590
MAGNETISMM-20
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05201781
Protocol IDs
CR109123
NCI-2022-01309
2020-005521-84
2023-505530-10-00
68284528MMY4002
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04973605
Protocol IDs
BGB-11417-105
NCI-2022-07236
2021-003614-39
U1111-1277-5444
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Phase II Study of CAR T-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
05396885
Protocol IDs
5.
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04910568
Protocol IDs
GO42552
NCI-2021-07543
2021-000238-33
6.
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT05651932
Protocol IDs
KTX-MMSET-001
NCI-2023-01697
EUCTR No: 2022-500801-41-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
A Study of Daratumumab
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05438043
Protocol IDs
CR109200
NCI-2024-00436
2021-006494-33
2022-500138-27-00
54767414MMY3030
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04133636
Protocol IDs
CR108581
2018-004124-10
68284528MMY2003
NCI-2019-07363
9.
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04634552
Protocol IDs
CR108920
NCI-2021-02134
2017-002400-26
2023-504581-29-00
TALMMY1001-PT3
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
10.
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05050097
Protocol IDs
CR108946
NCI-2021-13605
2020-004502-55
64407564MMY1004
11.
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04586426
Protocol IDs
CR108901
NCI-2023-06901
2019-004124-38
2023-503439-16-00
64007957MMY1003
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
12.
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT06045806
Protocol IDs
CA089-1043
NCI-2024-01211
2022-501346-30
U1111-1280-9736
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
13.
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT06121843
Protocol IDs
CA088-1005
NCI-2024-00171
Treatment Sites (2)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
NCORP Trial
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Cancer Type
Multiple Myeloma
NCT ID
NCT06271252
Protocol IDs
OriCAR-017 US-P1
NCI-2024-05382
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
15.
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Cancer Type
Multiple Myeloma
NCT ID
NCT05137054
Protocol IDs
R5458-ONC-2012
NCI-2022-03373
2020-004638-39
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Cancer Type
Multiple Myeloma
NCT ID
NCT06215118
Protocol IDs
C1071030
NCI-2024-03007
MagnetisMM-30
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
17.
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03601078
Protocol IDs
BB2121-MM-002
NCI-2018-01730
U1111-1216-4209
2018-000264-28
Treatment Sites (1)
Emory University School of Medicine
Atlanta
18.
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05208307
Protocol IDs
Winship5382-21
NCI-2021-08385
STUDY00003092
19.
NCORP Trial
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
20.
Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
Cancer Type
Lymphoma, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT06328699
Protocol IDs
EU6011-23
NCI-2023-09608
STUDY00006456
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04352205
Protocol IDs
WINSHIP4949-20
NCI-2020-01133
NCI-2020-01133
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03399799
Protocol IDs
CR108404
NCI-2018-00367
64407564MMY1001
2017-002400-26
23.
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03145181
Protocol IDs
CR108206
NCI-2017-01157
64007957MMY1001
2016-002122-36
24.
GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
Cancer Type
Hematopoietic Malignancies, Leukemia, Multiple Myeloma
NCT ID
NCT04824794
Protocol IDs
GCT3014-01
NCI-2021-05589
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
25.
Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04776395
Protocol IDs
WINSHIP5157-20
NCI-2020-08351
26.
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type
Bone Tumor, Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03858205
Protocol IDs
16M-18-2
NCI-2018-03600
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
27.
Melphalan before Stem Cell Transplant for the Treatment of Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04483206
Protocol IDs
WINSHIP5001-20
NCI-2020-04920
STUDY00000449
28.
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Cancer Type
Multiple Myeloma
NCT ID
NCT03732703
Protocol IDs
MyDRUG (MMRC-085)
NCI-2019-00698
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
29.
NCORP Trial
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type
Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor
NCT ID
NCT04314401
Protocol IDs
10323
10323
NCI-2020-00750
Treatment Sites (18)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Northside Hospital Cancer Institute - Forsyth
Cumming
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
30.
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma
NCT ID
NCT04975997
Protocol IDs
CC-220-MM-002
NCI-2021-08518
2020-000431-49
U1111-1260-2872
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
31.
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT03761108
Protocol IDs
R5458-ONC-1826
NCI-2019-02952
2018-003188-78
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
32.
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma
NCT ID
NCT04126200
Protocol IDs
208887
NCI-2020-01127
33.
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Cancer Type
Multiple Myeloma
NCT ID
NCT01838512
Protocol IDs
CA204-008
Treatment Sites (2)
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
34.
Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT03820817
Protocol IDs
Winship4480-18
NCI-2018-02106
IRB00106380
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
35.
NCORP Trial
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Cancer Type
Multiple Myeloma
NCT ID
NCT05396885
Protocol IDs
ARC-112A
NCI-2022-10407
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
36.
NCORP Trial
Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT06297226
Protocol IDs
CA088-1000
NCI-2024-02712
Treatment Sites (1)
Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
Atlanta
Caitlin Guzowski
404-851-8523
37.
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Cancer Type
Leukemia, Multiple Myeloma
NCT ID
NCT02952508
Protocol IDs
DCL-16-001
NCI-2017-01758
38.
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT04879043
Protocol IDs
HDP-101-01
NCI-2021-04304
39.
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma
NCT ID
NCT04756726
Protocol IDs
CFT7455-1101
NCI-2021-05587
40.
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT05317416
Protocol IDs
C1071007
NCI-2023-06350
2021-006052-14
MagnetisMM-7
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
41.
NCORP Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type
Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm
NCT ID
NCT02693535
Protocol IDs
Pro00014171
NCI-2017-00510
Treatment Sites (3)
City of Hope Atlanta
Newnan
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
42.
Testing the Addition of a New Drug, Daratumumab/rHuPH20, to the Usual Treatment (Lenalidomide) as Post-stem Cell Transplant Treatment for Multiple Myeloma, DRAMMATIC Study
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCT ID
NCT04071457
Protocol IDs
S1803
S1803
NCI-2018-02465
43.
NCORP Trial
Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Cancer Type
Multiple Myeloma
NCT ID
NCT03937635
Protocol IDs
EAA173
EAA173
NCI-2018-02611
44.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCT ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
45.
Venetoclax and Tocilizumab for the treatment of Patients with Relapsed or Refractory t(11;14) Multiple Myeloma
Cancer Type
Multiple Myeloma
NCT ID
NCT05391750
Protocol IDs
WINSHIP5273-21
NCI-2021-02510
STUDY00002448
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Georgia CORE bridges the gap between groundbreaking research, educational outreach, and effective advocacy to transform the landscape of cancer care for all Georgians.